|
WO9625186A2
|
|
Feedback controlled drug delivery system
|
|
US5674998A
|
|
C-4' modified adenosine kinase inhibitors
|
|
US5777100A
|
|
AICA riboside analogs
|
|
US5721356A
|
|
Orally active adenosine kinase inhibitors
|
|
US5775329A
|
|
Method and compounds for diagnosing coronary artery disease
|
|
US5726302A
|
|
Water soluble adenosine kinase inhibitors
|
|
US5646128A
|
|
Methods for treating adenosine kinase related conditions
|
|
WO9418215A1
|
|
Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
|
|
WO9417809A1
|
|
Adenosine deaminase inhibitor therapies
|
|
IL108524D0
|
|
Imidazodiazepine analogs
|
|
IL108525D0
|
|
Lyxofuranosyl derivatives
|
|
IL108523D0
|
|
Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
|
|
EP0670737A1
|
|
In vivo peptide therapy.
|
|
CA2134237A1
|
|
In vivo peptide therapy
|
|
US5443836A
|
|
Methods for protecting tissues and organs from ischemic damage
|
|
CA2115675A1
|
|
Method for lowering blood lipid levels
|
|
CA2100863A1
|
|
Adenosine kinase inhibitors
|
|
US5383848A
|
|
Iontophoretic administration of drugs
|
|
EP0262125A1
|
|
AICA riboside for the prophylactic treatment of diseases with restricted blood flow.
|
